Forward to: IP Team

Patent & IP Analytics
Workflows

Ten agent workflows for the IP Team — patent filing monitoring, IP landscape mapping, freedom-to-operate analysis, patent cliff tracking, biosimilar patent challenges, trade secret indicators, IP licensing intelligence, patent litigation tracking, regulatory exclusivity monitoring, and IP strategy dashboard — enabling data-driven intellectual property decisions powered by comprehensive domain intelligence.

1Patent Filing Monitor

AI agent monitors biotech and pharma company domains to detect new patent filings, continuation applications, and patent family expansions — providing early intelligence on IP strategy shifts.

1
Track Patent Filing Signals
/legal/investors/pressOpenPageRank
PATENT FILING INTELLIGENCE — 2,400 COMPANIES TRACKED ════════════════════════════════════════════════════════ lilly.com /legal: 14 new patent applications (tirzepatide formulations) /investors: Patent estate expansion — 340+ patents covering GLP-1 SIGNAL: Aggressive IP fortress strategy for obesity franchise abbvie.com /legal: 8 continuation applications for Rinvoq /press: Skinny label patent challenge from Teva SIGNAL: Defensive patent strategy — some claims under challenge modernatx.com /legal: 28 new mRNA delivery patents filed /press: Cross-license agreement with Arbutus resolved SIGNAL: mRNA IP position strengthening significantly

2Patent Cliff Tracking

AI agent monitors upcoming loss-of-exclusivity events across major pharma domains to track patent expiry dates, pediatric extensions, and market formation changes.

1
Track Patent Expiry Timeline
/legal/investors/productsIAB Categories
PATENT CLIFF TRACKER — NEXT 5 YEARS ════════════════════════════════════════════════════════ 2026 EXPIRIES: merck.com — Keytruda Revenue: $25B LOE: 2028 bms.com — Eliquis Revenue: $12B LOE: 2026 pfizer.com — Ibrance Revenue: $5B LOE: 2027 REVENUE AT RISK: 2026: $18B | 2027: $32B | 2028: $48B LIFECYCLE DEFENSE STRATEGIES DETECTED: New formulations filed: 14 products Indication expansions: 22 pending Authorized generics announced: 3 products

3Freedom-to-Operate Analysis

AI agent maps the patent landscape around specific drug targets and mechanisms to assess freedom-to-operate risks, identify blocking patents, and inform workaround strategies.

1
Assess FTO Landscape
/legal/products/pressOpenPageRank
FTO ANALYSIS — ADC LINKER-PAYLOAD SPACE ════════════════════════════════════════════════════════ BLOCKING PATENTS IDENTIFIED: seagen-archive.com — 48 patents on ADC linker technology daiichisankyo.com — 22 patents on DXd payload immunomedics-archive.com — 15 patents on SN-38 conjugation OPEN DESIGN SPACE: Novel payloads (non-MMAE, non-DXd): FTO clear Bispecific ADC formats: Limited blocking IP Site-specific conjugation (enzyme-mediated): Licensable FTO RECOMMENDATION: Proceed with novel payload class — design around existing IP License site-specific conjugation from Catalent ($5-8M upfront)

4Biosimilar Patent Challenges

AI agent monitors biosimilar developer and innovator domains to track BPCIA patent dance proceedings, IPR challenges, and settlement negotiations.

1
Track Biosimilar IP Challenges
/legal/press/investorsOpenPageRank
BIOSIMILAR PATENT CHALLENGE TRACKER ════════════════════════════════════════════════════════ sandoz.com vs amgen.com — Prolia/Xgeva /legal: 5 patents challenged via IPR /press: 2 patents invalidated — 3 remaining SIGNAL: Biosimilar launch possible 2027 — prepare defense biocon.com vs merck.com — Keytruda /legal: BPCIA notice letter filed — patent dance initiated /press: 28 patents listed in Purple Book SIGNAL: Extensive IP estate — likely delays biosimilar to 2030+ PATENT CHALLENGE SUMMARY: Active BPCIA proceedings: 14 products IPR challenges filed: 42 this year Settlement rate: 35% before trial

5Trade Secret & Know-How Indicators

AI agent detects trade secret and proprietary know-how signals by monitoring talent movement, NDA litigation, and manufacturing process disclosures across biotech domains.

1
Monitor Trade Secret Signals
/legal/careers/leadershipOpenPageRank
TRADE SECRET & KNOW-HOW INTELLIGENCE ════════════════════════════════════════════════════════ TALENT MOVEMENT ALERTS: competitor-biotech.com /leadership: VP Manufacturing departed to rival /legal: Trade secret lawsuit filed — TRO granted SIGNAL: Manufacturing know-how at risk — review protections NON-COMPETE EXPIRATIONS: 3 key scientists at competitor — non-competes expire Q3 2026 OPPORTUNITY: Recruitment window opening — engage headhunter TRADE SECRET PROTECTION AUDIT: Companies with active TS litigation: 8 this quarter Manufacturing process patents vs TS: Trend toward patenting

6IP Licensing Revenue Intelligence

AI agent monitors IP licensing and royalty streams across pharma domains to identify licensing revenue opportunities, royalty stacking risks, and licensing market dynamics.

1
Track IP Licensing Economics
/investors/press/legalIAB Categories
IP LICENSING REVENUE TRACKER ════════════════════════════════════════════════════════ qualcomm-bio-example.com — Platform IP Licensor /investors: Licensing revenue $420M (FY2025) /legal: 85 active licenses across industry SIGNAL: Platform IP licensing model proven — $400M+ annually ROYALTY RATE BENCHMARKS: Platform technology (antibody engineering): 2-5% Drug target IP: 1-3% Delivery technology (LNP, AAV): 3-7% Diagnostic biomarker: 1-2% OUR IP LICENSING OPPORTUNITIES: Licensable IP assets: 12 patent families Estimated licensing revenue potential: $80-120M/year

7Patent Litigation Tracking

AI agent monitors patent litigation activity across the biotech industry to track case outcomes, damages awards, injunctions, and settlement trends.

1
Track Patent Litigation
/legal/press/investorsOpenPageRank
PATENT LITIGATION TRACKER ════════════════════════════════════════════════════════ amgen.com vs sanofi.com /legal: Repatha patent case — Supreme Court ruling /press: Broad antibody genus claims invalidated SIGNAL: Industry-wide impact on antibody patent claiming modernatx.com vs pfizer.com /legal: mRNA COVID vaccine patent dispute /press: Settlement negotiations reported SIGNAL: Resolution likely — cross-license expected LITIGATION SUMMARY: Active pharma patent cases: 180+ in US courts Average damages award: $340M Settlement rate: 62% before trial

8Regulatory Exclusivity Monitor

AI agent monitors regulatory exclusivity periods beyond patents — orphan drug exclusivity, NCE exclusivity, pediatric extensions, and biosimilar reference product exclusivity — providing comprehensive LOE intelligence.

1
Track Regulatory Exclusivity
/compliance/investors/productsCountries
REGULATORY EXCLUSIVITY TRACKER ════════════════════════════════════════════════════════ ORPHAN DRUG EXCLUSIVITY EXPIRING 2026-2028: alexion.com — Soliris (PNH): Expired 2025 sarepta.com — Exondys 51 (DMD): Expires 2027 biomarin.com — Voxzogo (achon.): Expires 2029 PEDIATRIC EXCLUSIVITY EXTENSIONS: Filed: 8 products | Granted: 5 (+6 months each) Revenue protected: $4.2B annually NCE EXCLUSIVITY: Expiring 2026: 12 products Expiring 2027: 18 products

9Competitor IP Strategy Analysis

AI agent analyzes competitor patent filing patterns to decode IP strategy — identifying defensive vs. offensive filing behaviors, geographic priorities, and technology focus areas.

1
Decode Competitor IP Strategy
/legal/products/pressCountries
COMPETITOR IP STRATEGY ANALYSIS ════════════════════════════════════════════════════════ roche.com — IP Strategy: Fortress + Licensing Patent filings: 2,400+ (last 3 years) Geographic: US, EU, JP, CN, KR (broad coverage) Focus: Bispecific antibodies, ADCs, diagnostics SIGNAL: Building patent fortress around bispecific platform novartis.com — IP Strategy: Selective + Aggressive Patent filings: 1,800+ (last 3 years) Focus: Cell therapy, radioligand, gene therapy SIGNAL: Shifting IP focus to next-gen modalities INDUSTRY IP TRENDS: AI/ML-generated inventions: Patentability uncertain mRNA platform patents: Growing rapidly (+45% YoY)

10IP Strategy Dashboard

AI agent synthesizes all patent and IP intelligence into an executive dashboard — providing leadership with real-time visibility into IP landscape, competitive threats, and strategic opportunities.

1
Generate IP Intelligence Dashboard
/legal/investors/pressOpenPageRankIAB Categories
IP DASHBOARD — FEBRUARY 2026 ════════════════════════════════════════════════════════ OUR IP POSITION: Active patents: 480 | Pending applications: 120 FTO assessments completed: 8 this quarter Licensing revenue: $85M/year THREAT LANDSCAPE: Patent challenges against us: 4 active Biosimilar applicants: 3 products targeted OPPORTUNITIES: Licensable assets identified: 12 patent families FTO clear programs: 6 of 8 assessed
2
Generate IP Report

Patent & IP Report — February 2026

EXECUTIVE SUMMARY ──────────────────────────────────────── Companies monitored for IP activity: 2,400 domains Patent filings tracked: 12,000+ this quarter Active litigation cases: 180+ industry-wide Licensing deal value: $8.4B (annualized) KEY INSIGHTS Patent fortress strategies intensifying around GLP-1 and ADC assets. Biosimilar challenges accelerating — 42 IPR petitions this year. Gene editing IP landscape consolidating through cross-licenses. AI-generated invention patentability remains legally uncertain. Regulatory exclusivity increasingly critical as patent strategies mature.
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 100M+ domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.